Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
Lung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowle...
Saved in:
Main Authors: | Evan Pisick, Simha Jagadeesh, Ravi Salgia |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2004-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/tsw.2004.117 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01) -
Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01) -
Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation
by: K. Pollock, et al.
Published: (1993-01-01) -
Spleen tyrosine kinase inhibitors disrupt human neutrophil swarming and antifungal functions
by: Alex Hopke, et al.
Published: (2025-01-01) -
Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)